Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3245)	5/1/2015 7:33:41 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

SRNE was up 15.07% at its intraday H, but it closed up only 14.75% <g> Volume was abot 1.5x its ADV. It announced today that its subsidiary has acquired distribution rights from a South Korean corporation, to Cynviloq, which SRNE will mow sell in South America. <g> I have been following SRNE for some time and had bought and sold some its stock along the way.<g> P.Frost and OPK had a pretty good position, but sold a significant amount in 2013. But last Dec, SRNE and NantWorks formed a joint venture, to focus on immunotherapies for cancer and autoimmune diseases, and the stock has performed much better since then.<g>. They have been working in developing human monoclonal antibodies and antibody drug conjugate platforms that include proprietary conjugation chemistries, linkers and toxic payloads. Their strategy is to combate cancer with small molecules, mono- and bispecific therapeutic antibodies, ADCs and adoptive cellular immunotherapy.<g> At any rate, the stock has been performing well since Dec.<g> bigcharts.marketwatch.com And it did even better, a few yrs ago.<g> Bernard